Get the Stockscreener App
0.685
11.27%
-0.087
Pre-market:
.68
-0.005
-0.73%
Jupiter Neurosciences Inc stock is traded at $0.685, with a volume of 326.01K.
It is down -11.27% in the last 24 hours and down -51.42% over the past month.
Jupiter Neurosciences Inc is a clinical stage research and development pharmaceutical company located in Jupiter, Florida. The company has developed a unique resveratrol platform product primarily targeting treatment of neuro-inflammation. Its platform product, JOTROL, offers potential therapeutic benefit to most central nervous system diseases such as Alzheimer's disease, ataxias, and metabolic disorders such as Lysosomal Storage Disorders and mitochondrial diseases.
See More
Previous Close:
$0.772
Open:
$0.8102
24h Volume:
326.01K
Relative Volume:
0.47
Market Cap:
$22.68M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-7.7664
EPS:
-0.0882
Net Cash Flow:
-
1W Performance:
-18.26%
1M Performance:
-51.42%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$0.6521
$0.8102
1-Week Range:
$0.6521
$0.8727
52-Week Range:
$0.6521
$19.51
Jupiter Neurosciences Inc Stock (JUNS) Company Profile
Name
Jupiter Neurosciences Inc
Sector
Industry
Phone
(561) 406-6154
Address
1001 NORTH US HWY 1, JUPITER
Compare JUNS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
JUNS
Jupiter Neurosciences Inc
|
0.685 | 22.68M | 0 | 0 | 0 | -0.0882 |
|
VRTX
Vertex Pharmaceuticals Inc
|
480.35 | 123.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
723.47 | 79.09B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
624.94 | 37.97B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.20 | 31.74B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
259.70 | 27.71B | 3.32B | -860.46M | -1.04B | -8.32 |
Jupiter Neurosciences Inc Stock (JUNS) Latest News
Jupiter Neurosciences Inc (JUNS) Shares Decline Despite Market Challenges - The News Heater
Jupiter Neurosciences partners with Catalent for Parkinson’s trial By Investing.com - Investing.com Nigeria
Three technology stocks with differentiated value propositions | 2025-02-07 | Investing News - Stockhouse Publishing
Jupiter Neurosciences partners with Catalent for Parkinson's trial - MSN
Jupiter Neurosciences Addresses Market Volatility as it - GlobeNewswire
Jupiter Neurosciences says volatility ‘appears to be driven by misconceptions’ - TipRanks
Jupiter Neurosciences Addresses Market Volatility as it Remains Focused on Advancing Clinical and Commercial Milestones - TradingView
Jupiter Neurosciences Partners With Catalent For Parkinson's JOTROL Trial Production - Nasdaq
Jupiter Neurosciences Signs Manufacturing Deal With Catalent Pharma for Jotrol Softgel Capsules - Marketscreener.com
Jupiter Neurosciences Partners with Catalent to Produce JOTROL Softgels for Upcoming Clinical Trial - Contract Pharma
Jupiter Neurosciences partners with Catalent for Parkinson's trial By Investing.com - Investing.com South Africa
Clinical Trials News Live Feed - StockTitan
Jupiter Neurosciences Announces JOTROL Manufacturing - GlobeNewswire
Jupiter Neurosciences Announces JOTROL Manufacturing Agreement with Catalent to Support Phase 2a Parkinson's Trial - The Manila Times
Major Breakthrough: New Parkinson's Drug Manufacturing Deal Could Fast-Track Treatment for 10M Patients - StockTitan
Jupiter Neurosciences partners with Zina for Parkinson's trial - Investing.com India
Jupiter Neurosciences, Zina Biopharmaceuticals Collaborate on Phase 2a Parkinson's Disease Study - Marketscreener.com
Jupiter Neurosciences Partners with Zina Biopharmaceuticals to Advance Phase 2a Parkinson’s Trial - GlobeNewswire
Jupiter Neurosciences partners with Zina for Parkinson's trial By Investing.com - Investing.com South Africa
Wall Street Set to Open Slightly Lower Friday as Investors Await PMI, Housing Figures - TradingView
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
United States shares higher at close of trade; Dow Jones Industrial Average up 0.93% - Investing.com India
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.93% - Investing.com
U.S. shares higher at close of trade; Dow Jones Industrial Average up 0.93% - Investing.com UK
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Stock market news: Chanson International Holdings declined by 83.97% while Dogwood Therapeutics surged by 387.32% during mid day trading - Business Upturn
Stock market today: Icon Energy surged by 222.66% while Jupiter Neurosciences gained over 208.62% in early trading - Business Upturn
US Stocks Mixed; GE Aerospace Posts Upbeat Earnings - Benzinga
Modest Final Quarter Completes Shaky Biotech IPO Comeback For 2024 - News & Insights
Stock market news: Star Fashion Culture Holdings -78.42%, Lisata Therapeutics -33.08% among biggest losers in early trading - Business Upturn
Stock market today: Star Fashion Culture Holdings -79.05%, Lisata Therapeutics -23.34% among biggest losers in early trading - Business Upturn
Twin Vee PowerCats Co. New 5-Axis CNC Router to Harness Advanced Robotics in Production Process - The Globe and Mail
Biopharma IPOs rebound slightly, as class of 2024 lags with a 29% average decline - BioWorld Online
Jupiter Neurosciences refocuses on NLRP3 inflammasome By Investing.com - Investing.com South Africa
Jupiter Neurosciences refocuses on NLRP3 inflammasome - Investing.com India
Jupiter Neurosciences Announces Strategic Focus on NLRP3 Pathway in Future JOTROL™ Trials - GlobeNewswire
Jupiter Neurosciences announces focus on NLRP3 pathway in JOTROL trials - TipRanks
Jupiter Neurosciences Targets NLRP3 Inflammasome With JOTROL Platform for Alzheimer's Treatment - StockTitan
Pre-market Movers: ONCO, EYEN, SGMO, VSTM... - RTTNews
December's $4.69B in biopharma financings caps a $102.15B year - BioWorld Online
Jupiter Neurosciences Inc. (JUNS) reports earnings - Quartz
Jupiter Neurosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Jupiter Neurosciences inks deal for Southeast Asia expansion By Investing.com - Investing.com Australia
Jupiter Neurosciences inks deal for Southeast Asia expansion - Investing.com
Jupiter Neurosciences adjusts CFO compensation - Investing.com
Greenridge sees upside in Jupiter Neurosciences stock By Investing.com - Investing.com Canada
Jupiter Neurosciences initiated with a Buy at Greenridge - Nasdaq
Finance Watch: FOPO Surge Continues With Big Offerings From Revolution, NewAmsterdam - Citeline News & Insights
Tesla, Nvidia among Tuesday's market cap stock movers - Investing.com
Tesla, Nvidia among Tuesday's market cap stock movers By Investing.com - Investing.com UK
RCI Hospitality, Quantum Computing, Teva Pharmaceutical, Tesla And Other Big Stocks Moving Higher On Monday - Benzinga
Jupiter Neurosciences Inc Stock (JUNS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.53%
0.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):